Vectus Biosystems Limited (ASX:VBS)

Australia flag Australia · Delayed Price · Currency is AUD
0.125
0.00 (0.00%)
Apr 28, 2026, 3:10 PM AEST
56.25%
Market Cap 6.68M
Revenue (ttm) 89.96K
Net Income (ttm) -1.41M
Shares Out 53.43M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 164,640
Average Volume 47,822
Open 0.130
Previous Close 0.125
Day's Range 0.125 - 0.130
52-Week Range 0.037 - 0.455
Beta 0.30
RSI 44.08
Earnings Date May 27, 2026

About Vectus Biosystems

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue to fibrosis, and scarring. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohe... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 8
Stock Exchange Australian Securities Exchange
Ticker Symbol VBS
Full Company Profile

Financial Performance

In fiscal year 2025, Vectus Biosystems's revenue was 478,182, a decrease of -58.01% compared to the previous year's 1.14 million. Losses were -1.78 million, -23.99% less than in 2024.

Financial Statements

News

XORTX Extends Closing Of Renal Anti-Fibrotic Therapeutic Program Acquisition; Stock Soars

(RTTNews) - XORTX Therapeutics Inc. (XRTX), a late-stage clinical pharmaceutical company that develops therapies for gout and progressing kidney diseases, has entered into an extension agreement with ...

2 months ago - Nasdaq